DHEAS
metaboliteDHEAS is a steroid hormone whose altered metabolism associates with dyspnea in antiplatelet therapy, reflecting systemic drug response.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleSteroid hormone; ticagrelor-associated side effect marker; off-pathway.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II60
A — assay feasibility42
E — evidence strength22
T1DI (composite)3
Specificity differential (R−C)-40.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Plasma metabolomic profiling of patients with acute coronary syndrome treated with potent platelet inhibitors.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026 · PMID 41564597 · doi